Signal Averaged Electrocardiography (SAECG)
Signal-averaged electrocardiography (SAECG) has been proposed as a test to predict which individuals are at highest risk of experiencing an arrhythmic event (either a sustained arrhythmia or sudden cardiac death). Because sudden cardiac death, whether from arrhythmias or pump failure, is one of the most common causes of death after a previous myocardial infarction, there is intense interest in risk stratification to determine target therapy. SAECG involves computerized analysis of small segments of a standard ECG to detect abnormalities. Signals are first amplified, then filtered, and finally averaged with the assistance of computer software.
Signal-averaged electrocardiography is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
The available literature does not validate the use of SAECG for predicting which individuals are at highest risk of experiencing an arrhythmic event. No trials were found in which use of SAECG was shown to improve outcomes.
American College of Cardiology, American Heart Association Task Force, Heart Rhythm Society. (2017). 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Retrieved September 7, 2018 from www.acc.org.
American College of Cardiology. (1996). ACC Expert Consensus Document. Signal-averaged electrocardiography. Retrieved September 7, 2018 from www.acc.org.
Jongman, J. K., Zaidi, A., Muggenthaler, M. & Sharma, S. (2015). Relationship between echocardiographic right-ventricular dimensions and signal-averaged electrocardiogram abnormalities in endurance athletes. Europace, 17 (9), 1441-1448. Abstract retrieved November 7, 2016 from PubMed database.
Kanzaki, Y., Inden, Y., Ando, M., Kamikubo, Y., Ito, T., Mizutani, Y., et al. (2016). An ECG index of P-wave force predicts the recurrence of atrial fibrillation after pulmonary vein isolation. Pacing Clinical Electrophysiology, 39 (11), 1191-1197. Abstract retrieved October 4, 2017 from PubMed database.
Mendes, V. N., Pereira, T. S., & Matos, V. A. (2016). Diagnosis of rejection by analyzing ventricular late potentials in heart transplant patients. Arquivos Brasileiros de Cardiologia, 106 (2), 136-144. Abstract retrieved November 7, 2016 from PubMed database.
Pandey, A. K.., Das, A., Singwala, A. K. & Bhatt, K. N. (2010). Prediction and stratification of the future cardiovascular arrhythmic events: signal averaged electrocardiography versus ejection fraction. Indian Journal of Physiology and Pharmacology, 54 (2), 123-132. Abstract retrieved December 3, 2015 from PubMed database.
Proclemer, A., Lewalter, T., Bongiorni, M.G., Svendsen, J.H., Pison, L., Lundgyist, C.B. (2013). Screening and risk evaluation for sudden cardiac death in ischaemic and non-ischaemic cardiomyopathy: results of the European Heart Rhythm Association survey. Europace, 15 (7), 1059-1062. Abstract retrieved September 10, 2018 from PubMed database.
Yodogawa, K., Seino, Y., Ohara, T., Hayashi, M., Miyauchi, Y., Katoh, T., et al. (2013). Prediction of atrial fibrillation after ischemic stroke using P-wave signal averaged electrocardiography. Journal of Cardiology, 61 (1), 49-52. Abstract retrieved November 7, 2016 from PubMed database.
ORIGINAL EFFECTIVE DATE: 7/1986
MOST RECENT REVIEW DATE: 10/11/2018
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.